-
Detailed Analysis Download Full Stock Report Add to Watchlist
Values as of: 2022-05-16
Last Closing Price
USD 0.12Change
0.00 (0.00)%Market Cap
USD 0.15BVolume
1.67MYahoo Analyst Target
N/AAvg Analyst Target
N/A
N/A
Verdict
Values as of: 2022-05-16
Last Closing Price
USD 0.12Change
0.00 (0.00)%Market Cap
USD 0.15BVolume
1.67MYahoo Analyst Target
N/AAvg Analyst Target
N/AN/A
Verdict
As of May 9, 2019, was acquired by C3J Therapeutics, Inc., in a reverse merger transaction.
Company Website : http://www.ampliphibio.com
Address : 3579 Valley Centre Drive, Suite 100 92130,San Diego,USA
Employees : 30
Fiscal Year End : December
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap | Price / Earning Ratio | EV/EBITDA |
---|---|---|---|---|---|
BMS | Bemis Company, Inc |
N/A |
USD370,676,430.93B | 1,000,000.00 | N/A |
NAO | Nordic American Offshore Ltd |
N/A |
USD387,070.41B | N/A | N/A |
ITC | ITC Holdings Corp |
N/A |
USD3,166.52B | 22.84 | N/A |
MSF | Morgan Stanley Emerging Market.. |
N/A |
USD1,000.65B | 24.60 | N/A |
HSBC-PA | HSBC Holdings plc ADR A 1/40PF.. |
N/A |
USD513.94B | 53.22 | N/A |
SAN-PB | Banco Santander, S.A. GTD PFD .. |
N/A |
USD384.67B | 54.97 | N/A |
BAC-PW | Bank of America Corporation |
N/A |
USD267.69B | 9.46 | N/A |
BAC-PY | Bank of America Corporation |
N/A |
USD263.53B | 9.36 | N/A |
BEL | Belmond Ltd |
N/A |
USD261.58B | 15.94 | N/A |
NEE-PR | NextEra Energy, Inc |
N/A |
USD103.76B | 9.93 | N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|
N/A
Market Performance vs. Industry/Classification (Other) |
Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 12 Months | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 1.22% | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 1.22% | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 4.47% | N/A | N/A | N/A | N/A | ||
Risk Adjusted Return | 27.32% | N/A | N/A | N/A | N/A | ||
Market Capitalization | 0.15B | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 87%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Ratio vs. Industry/Classification (Other) |
Ratio vs. Market |
||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
Market Value | |||||||
Price / Earning Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price/Book Ratio | N/A | N/A | N/A | N/A | N/A | ||
Price / Cash Flow Ratio | -15.88 | N/A | N/A | N/A | N/A | ||
EV/EBITDA | N/A | N/A | N/A | N/A | N/A | ||
Management Effectiveness | |||||||
Return on Equity | N/A | N/A | N/A | N/A | N/A | ||
Return on Invested Capital | -126.70% | N/A | N/A | N/A | N/A | ||
Return on Assets | N/A | N/A | N/A | N/A | N/A | ||
Debt to Equity Ratio | N/A | N/A | N/A | N/A | N/A | ||
Technical Ratios | |||||||
Dividend Yield | N/A | N/A | N/A | N/A | N/A | ||
Short Ratio | N/A | N/A | N/A | N/A | N/A | ||
Short Percent | N/A | N/A | N/A | N/A | N/A | ||
Beta | N/A | N/A | N/A | N/A | N/A |
Letter Grade | Percentage | Letter Grade | Percentage | Letter Grade | Percentage |
A+ | 97%-100% | A | 93%-96% | A- | 90%-92% |
B+ | 97%-89% | B | 83%-86% | B- | 80%-82% |
C+ | 77%-79% | C | 73%-76% | C- | 70%-72% |
D+ | 67%-69% | D | 63%-66% | D- | 60%-62% |
F | 0%-59% |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
No discussions yet
User Name | Target Rating | Target Horizon (Months) | Target Price | User Analysis | Date | Comment |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
The company had negative total cash flow in the most recent four quarters.